metaPreg - Lansoprazole during pregnancy

Lansoprazole updated on 01-14-2026

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	1.08 [0.96, 1.21]	6%	6 studies	115,310	11,105	not evaluable	ROB	-
Major congenital malformations	1.08 [0.96, 1.21]	6%	6 studies	115,310	11,105	not evaluable	ROB	-
Hypospadias	1.57 [0.70, 3.51]	13%	3 studies	3,342	3,309	not evaluable	ROB	-
Atrial septal defect	49.70 [1.92, 1288.78]	-	1 study	1	13	not evaluable	ROB	98.89 [3.24; .]
9 non statistically significant endpoints reported in only one study
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Low birth weight (< 2500g)	0.91 [0.83, 1.00]	0%	2 studies	104,657	8,774	not evaluable	ROB	-
Preterm (< 37 weeks)	1.64 [0.93, 2.88]	0%	2 studies	164	144	not evaluable	ROB	-
Long term consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Childhood asthma	1.70 [1.38, 2.09]	-	1 study		346	not evaluable	ROB	2.79 [2.10; .]
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Early intrauterine deaths (< 22 weeks) / Spontaneous abortions	1.39 [0.75, 2.57]	0%	2 studies	149	168	not evaluable	ROB	-
Elective/induced termination of pregnancy	3.79 [1.85, 7.76]	0%	2 studies	52	168	not evaluable	ROB	7.03 [3.10; .]
Late intrauterine deaths (> 22 weeks) / Stillbirths	1.91 [0.23, 15.48]	0%	2 studies	8	159	not evaluable	ROB	-
Ectopic pregnancy	-	-	0 study					-
Neuro-developmental disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
1 non statistically significant endpoints reported in only one study